p16 expression in odontogenic tumors

Tumori

Volumn 94, Issue 5, 2008, Pages 718-723

  Artese, Luciano ^a   Piattelli, Adriano ^a   Rubini, Corrado ^b   Goteri, Gaia ^b   Perrotti, Vittoria ^a   Iezzi, Giovanna ^a   Piccirilli, Marcello ^a   Carinci, Francesco ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Cell cycle proteins; Immunohistochemistry; Odontogenic tumors; p16

Indexed keywords

PROTEIN P16;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ODONTOGENIC TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STATISTICAL SIGNIFICANCE; TUMOR RECURRENCE;

EID: 56749131167     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400513     Document Type: Article

References (46)

1. rd ed, pp 323-356, WB Saunders, Philadelphia, 1999.
2. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilczynski S, Lee YY, Bartram CR, Koeffler HP: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res, 55: 2266-2269, 1995.
3. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366: 704-707, 1993.
4. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R: Beach, p21 is a universal inhibitor of cyclin kinases. Nature, 366: 701-704, 1993.
5. Huang L, Goodrow TL, Zhang SY, Klein-Szanto AJ, Chang H, Ruggeri BA: Deletion and mutation analyses of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res, 56: 1137-1141, 1996.
6. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stocken E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264: 436-440, 1994.
7. INK4a/RB/ cyclin D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus. Hum Pathol, 33: 1120-1125, 2002.
8. Grana X, Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 11: 211-219, 1995.
9. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
10. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J: Cloning of p27 Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
11. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D: Inhibition of ras-induced proliferation and cellular transforma-tion by p 16INK4. Science, 267: 249-252, 1995.
12. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
13. Ghiorzo P, Villaggio B, Sementa AR, Hansson J, Platz A, Nicolo G, Spina B, Canepa M, Palmer JM, Hayward NK, Bianchi-Scarra G: Expression and localization of mutant p16 proteins in melanocytic lesions from melanoma patients. Hum Pathol, 35: 25-33, 2004.
14. Kang YK, Kim WH, Jang JJ: Expression of G1-S modulators (p53, p16, p27, cyclin D1, R6) and SMAD4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol, 33: 877-883, 2002.
15. INK4A and early endocervical glandular neoplasia. Hum Pathol, 33: 899-904, 2002.
16. Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T: Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer, 84: 225-233, 1999.
17. Hirabayashi S: Immunohistochemical detection of DNA topoisomerase type IIa and Ki-67 in adenoid cystic carcinoma and pleomorphic adenoma of the salivary gland. J Oral Pathol Med, 28: 131-136, 1999.
18. Maeyama H, Furuwatari C, Ota H, Akamatsu T, Nakayama J, Katsuyama T: Histone H3 messenger RNA in situ hybridization for identifying proliferating cells in formalin-fixed rat gastric mucosa. Histochem J, 29: 867-873, 1997.
19. Yabuki N, Sasano H, Kato K, Ohara S, Toyota T, Nagura H, Miyaike M, Nozaki N, Kikuchi A: Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am J Pathol, 149: 997-1007, 1996.
20. Donnellan R, Chetty R: Cyclin D1 and human neoplasia. Mol Pathol, 51: 1-7, 1998.
21. Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu SH, Harris CC, Montesano R, Weinstein IB: Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA, 90: 9026-9030, 1993.
22. Kudo Y, Takata T, Ogawa I, Sato S, Nikai H: Expression of p53 and p21 CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas. Oncol Rep, 6: 539-545, 1999.
23. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med, 3: 231-234, 1997.
24. Moriya T, Sakamoto K, Sasano H, Kawanaka M, Sonoo H, Manabe T, Ito J: Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases. Mod Pathol, 13: 13-18, 2000.
25. Pande P, Mathur M, Shukla NK, Ralhan R: pRb and p16 protein alterations in human oral tumorigenesis. Eur J Cancer B Oral Oncol, 34: 396-403, 1998.
26. Sano T, Hikino T, Xue Q, Saito T, Kashiwabara K, Oyama T, Nakajima T: Immuno-histochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int, 48: 580-585, 1998.
27. Shoji M, Dobashi Y, Morinaga S, Jiang SX, Kameya T: Tumor extension and cell proliferation in adenocarcinomas of the lung. Am J Pathol, 154: 909-918, 1999.
28. van Oijen MG, Tilanus MG, Medema RH, Slootweg PJ: Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression. J Oral Pathol Med, 27: 367-375, 1998.
29. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB: Distinct patterns of inactivation of p15 and p16 characterize the major types of haematological malignancies. Cancer Res, 57: 837-841, 1997.
30. Liggett WH, Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol, 16: 1197-1206, 1998.
31. Kobayashi S, Shirasawa H, Sashiyama H, Kawahira H, Kaneko K, Asano T, Ochiai T: p16 INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin Cancer Res, 5: 4182-4185, 1999.
32. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussein SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC: Mutations and altered expression of p16 INK4 in human cancer. Proc Natl Acad Sci USA, 91: 11045-11049, 1994.
33. Kumamoto H, Kimi K, Ooya H: Detection of cell cycle-related factors in ameloblastomas. J Oral Pathol Med, 30: 309-315, 2001.
34. Schreiber M, Muller WJ, Singh G, Graham FL: Comparison of the effectiveness of adenovirus vectors expressing cyclinkinase inhibitors p16 INK4a, p18 INK4c, p19 INK4d, p21 WAF1/CIP1 and p27 KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene, 18: 1663-1676, 1999.
35. Hall M, Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. Adv Cancer Res, 68: 67-108, 1996.
36. Hunter T, Pines J: Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
37. Barnes L, Eveson JW, Reichart P, Sidransky D (Eds): Head and Neck Tumours, Pathology and Genetics, WHO Classification of Tumours. IARC Press, Lyon, 2005.
38. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med, 1: 686-692, 1995.
39. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers, Nature, 368: 753-756, 1994.
40. Okamoto A, Hussain SP, Hagiwara K, Spillare EA, Rusin MR, Demetrick DJ, Serrano M, Hannon GJ, Shiseki M, Zariwala M: Mutations in the p16INK4/ MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res, 55: 1448-1451, 1995.
41. Shintani S, Mihara M, Nakahara Y: Infrequent alterations of RB pathway (Rb-p16 INK4A-cyclin D1) in adenoid cystic carcinoma of salivary glands. Anticancer Res, 20: 2169-2175, 2000.
42. Reed AL, Califano J, Cairns P, Weatra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D: High frequency of p16 inactivation in head and neck squamous cell carcinoma. Cancer Res, 56: 3630-3633, 1996.
43. Yuen P, Man M, Yin Lam K, Lam Kwong Y: Clinicopathologic significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinoma. J Clin Pathol, 55: 58-60, 2002.
44. Lang JC, Borchers J, Danahey D, Smith S, Stover DG, Agrawal A, Malone JP, Schuller DE, Weghorst CM, Holinga AJ, Lingam K, Patel CR, Esham B: Mutational Status or overexpressed p16 in head and neck cancer: evidence for germline mutation of p16/p14 ARF. Int J Oncol, 21: 401-408, 2002.
45. Natarajan E, Saeb M, Crum CP, Woo SB, McKee PH, Rheinwald JG: Co-expression of p16 (INK4A) and laminin 5 gamma 2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol, 163: 477-491, 2003.
46. Chen Q, Luo G, Li B, Samaranayake LP: Expression of p16 and CDK4 in oral premalignant lesions and oral squamous cell carcinomas: a semiquantitative immunohistochemical study. J Oral Pathol Med, 28:158-164, 1999.